CEMAD Centro Malattie dell'Apparato Digerente, Medicina Interna e Gastroenterologia, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
Centro Pancreas, Chirurgia Digestiva, Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, 00168 Rome, Italy.
Int J Mol Sci. 2024 Jul 11;25(14):7623. doi: 10.3390/ijms25147623.
Pancreatic cancer (PC) is an increasing cause of cancer-related death, with a dismal prognosis caused by its aggressive biology, the lack of clinical symptoms in the early phases of the disease, and the inefficacy of treatments. PC is characterized by a complex tumor microenvironment. The interaction of its cellular components plays a crucial role in tumor development and progression, contributing to the alteration of metabolism and cellular hyperproliferation, as well as to metastatic evolution and abnormal tumor-associated immunity. Furthermore, in response to intrinsic oncogenic alterations and the influence of the tumor microenvironment, cancer cells undergo a complex oncogene-directed metabolic reprogramming that includes changes in glucose utilization, lipid and amino acid metabolism, redox balance, and activation of recycling and scavenging pathways. The advent of omics sciences is revolutionizing the comprehension of the pathogenetic conundrum of pancreatic carcinogenesis. In particular, metabolomics and genomics has led to a more precise classification of PC into subtypes that show different biological behaviors and responses to treatments. The identification of molecular targets through the pharmacogenomic approach may help to personalize treatments. Novel specific biomarkers have been discovered using proteomics and metabolomics analyses. Radiomics allows for an earlier diagnosis through the computational analysis of imaging. However, the complexity, high expertise required, and costs of the omics approach are the main limitations for its use in clinical practice at present. In addition, the studies of extracellular vesicles (EVs), the use of organoids, the understanding of host-microbiota interactions, and more recently the advent of artificial intelligence are helping to make further steps towards precision and personalized medicine. This present review summarizes the main evidence for the application of omics sciences to the study of PC and the identification of future perspectives.
胰腺癌(PC)是癌症相关死亡的一个日益增加的原因,其预后不良是由于其侵袭性生物学特性、疾病早期缺乏临床症状以及治疗无效所致。PC 的特征是复杂的肿瘤微环境。其细胞成分的相互作用在肿瘤的发展和进展中起着至关重要的作用,导致代谢改变和细胞过度增殖,以及转移进化和异常的肿瘤相关免疫。此外,为了应对内在的致癌改变和肿瘤微环境的影响,癌细胞经历了一种复杂的癌基因定向代谢重编程,包括葡萄糖利用、脂质和氨基酸代谢、氧化还原平衡以及循环和清除途径的激活的改变。组学科学的出现正在彻底改变对胰腺发生癌变的发病机制的理解。特别是,代谢组学和基因组学使得 PC 能够更精确地分为具有不同生物学行为和对治疗反应的亚型。通过药物基因组学方法识别分子靶点可能有助于实现个体化治疗。使用蛋白质组学和代谢组学分析发现了新的特异性生物标志物。放射组学通过对影像学的计算分析实现了更早的诊断。然而,目前组学方法的复杂性、高专业性和成本是其在临床实践中应用的主要限制。此外,外泌体(EVs)的研究、类器官的使用、宿主-微生物群相互作用的理解以及最近人工智能的出现,都有助于在精准和个性化医学方面取得进一步的进展。这篇综述总结了将组学科学应用于 PC 研究和确定未来展望的主要证据。